Stocks · News reference

Cerenome Highlights REYOBIQ Clinical Data And CNSide Health Economics Findings At 2026 SNO/ASCO CNS Metastases Conference

Aug 20, 2026, 11:36 AMBenzinga Newsdesk

Pharmacokinetic and dosimetry findings of Reyobiq from RESPECT-LM single dose study shows broad CSF compartmental distribution and on target drug activity. Update on ongoing multidose leptomeningeal metastases trial

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CNSY

Source: benzinga
Observed: Aug 20, 2026, 11:36 AM
Checked: Aug 20, 2026, 11:36 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 14, 2026, 9:12 PMBenzinga Newsdesk
Cerenome Q2 EPS $(1.31) Misses $(0.85) Estimate, Sales $411.000K Miss $1.110M Estimate
Cerenome (NASDAQ:CNSY) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(0.85) by 54.12 percent. This is a 718.75 percent decrease over losses of $(0.16) per share from the
Read original at benzinga
CNSY
BenzingaAug 13, 2026, 11:34 AMBenzinga Newsdesk
Cerenome Announces In-Network Provider Agreement With Health Care Service Corporation For CNSide CSF Assay, Effective August 1; Total Contracted Coverage Reaches About 153 Million
Read original at benzinga
CNSY

Cerenome Highlights REYOBIQ Clinical Data And CNSide Health Economics Findings At 2026 SNO/ASCO CNS Metastases Conference

Connected markets

Related headlines

Cerenome Q2 EPS $(1.31) Misses $(0.85) Estimate, Sales $411.000K Miss $1.110M Estimate

Cerenome Announces In-Network Provider Agreement With Health Care Service Corporation For CNSide CSF Assay, Effective August 1; Total Contracted Coverage Reaches About 153 Million